Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis (Oskira ABPM)
OSKIRA-ABPM: A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients With Rheumatoid Arthritis
The purpose of this study is to evaluate the effect of fostamatinib compared to placebo on ambulatory blood pressure in patients with active rheumatoid arthritis who are taking a disease-modifying anti-rheumatic drug (DMARD).
The study will last for 57 days.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Sevlievo, Bulgaria
- Research Site
-
Sofia, Bulgaria
- Research Site
-
-
-
-
-
Brno, Czech Republic
- Research Site
-
Hlucin, Czech Republic
- Research Site
-
Hostivice, Czech Republic
- Research Site
-
Kladno, Czech Republic
- Research Site
-
Ostrava-Trebovice, Czech Republic
- Research Site
-
Praha 11, Czech Republic
- Research Site
-
Praha 2, Czech Republic
- Research Site
-
Praha 4, Czech Republic
- Research Site
-
-
-
-
-
Aachen, Germany
- Research Site
-
Halle, Germany
- Research Site
-
-
-
-
-
Gdynia, Poland
- Research Site
-
Grodzisk Mazowiecki, Poland
- Research Site
-
Kalisz, Poland
- Research Site
-
Katowice, Poland
- Research Site
-
Poznan, Poland
- Research Site
-
Sroda Wielkopolska, Poland
- Research Site
-
Wroclaw, Poland
- Research Site
-
Łódź, Poland
- Research Site
-
-
-
-
-
Bloemfontein, South Africa
- Research Site
-
Cape Town, South Africa
- Research Site
-
Durban, South Africa
- Research Site
-
Kempron Park, South Africa
- Research Site
-
-
-
-
-
Donetsk, Ukraine
- Research Site
-
Kyiv, Ukraine
- Research Site
-
Vinnytsia, Ukraine
- Research Site
-
Zaporizhzhya, Ukraine
- Research Site
-
Zaporozhye, Ukraine
- Research Site
-
-
-
-
Alabama
-
Huntsville, Alabama, United States
- Research Site
-
-
California
-
Huntington Beach, California, United States
- Research Site
-
Santa Maria, California, United States
- Research Site
-
-
Connecticut
-
Trumbull, Connecticut, United States
- Research Site
-
-
Florida
-
Boca Raton, Florida, United States
- Research Site
-
Brandon, Florida, United States
- Research Site
-
Orlando, Florida, United States
- Research Site
-
Tampa, Florida, United States
- Research Site
-
Venice, Florida, United States
- Research Site
-
-
Georgia
-
Decatur, Georgia, United States
- Research Site
-
-
Indiana
-
South Bend, Indiana, United States
- Research Site
-
-
Maryland
-
Cumberland, Maryland, United States
- Research Site
-
Frederick, Maryland, United States
- Research Site
-
Hagerstown, Maryland, United States
- Research Site
-
-
Missouri
-
Florissant, Missouri, United States
- Research Site
-
Richmond Heights, Missouri, United States
- Research Site
-
-
New Jersey
-
Freehold, New Jersey, United States
- Research Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States
- Research Site
-
-
New York
-
Brooklyn, New York, United States
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, United States
- Research Site
-
Greensboro, North Carolina, United States
- Research Site
-
-
Oregon
-
Lake Oswego, Oregon, United States
- Research Site
-
-
Pennsylvania
-
Duncansville, Pennsylvania, United States
- Research Site
-
-
Tennessee
-
Memphis, Tennessee, United States
- Research Site
-
-
Texas
-
Austin, Texas, United States
- Research Site
-
Dallas, Texas, United States
- Research Site
-
Houston, Texas, United States
- Research Site
-
Lubbock, Texas, United States
- Research Site
-
Nassau Bay, Texas, United States
- Research Site
-
-
Washington
-
Tacoma, Washington, United States
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patients aged 18 or over diagnosed with rheumatoid arthritis after the age of 16
- Active rheumatoid arthritis defined as: ≥4 swollen joints and ≥4 tender/painful joints (from 28 joint count) and either erythrocyte sedimentation rate ≥28 mm/h, or C-reactive protein ≥10 mg/L.
- Currently taking one of the following disease-modifying anti-rheumatic drugs: methotrexate, sulfasalazine, hydroxychloroquine or chloroquine.
- Patients without essential hypertension or with essential hypertension if their blood pressure is controlled (<140/90 mmHg) with anti-hypertensive medications being stable at least 4 weeks prior to randomisation.
Exclusion Criteria:
- Females who are pregnant or breastfeeding.
- Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders
- History of liver problems that have required previous investigations
- Evidence of tuberculosis infection
- Conditions that preclude or render difficult the 24-hour ambulatory blood pressure monitoring technique.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dosing Regimen A
Oral treatment
|
fostamatinib 100 mg twice daily
|
|
Placebo Comparator: Dosing Regimen B
Oral treatment
|
placebo
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in 24-hour Mean Ambulatory SBP
Time Frame: 4 weeks
|
ANCOVA=analysis of covariance, BID=twice daily, FAS=full analysis set, IP=investigational product, SBP=systolic blood pressure.
|
4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in 24-hour Mean Ambulatory DBP
Time Frame: 4 weeks
|
ANCOVA=analysis of covariance, BID=twice daily, DBP=diastolic blood pressure, FAS=full analysis set, IP=investigational product.
|
4 weeks
|
|
Change From Baseline in Mean Daytime and Night-time SBP and DBP by Ambulatory Blood Pressure Monitoring
Time Frame: 4 weeks
|
ANCOVA=analysis of covariance, BID=twice daily, DBP=diastolic blood pressure, FAS=full analysis set, IP=investigational product, SBP=systolic blood pressure.
|
4 weeks
|
|
Change From Baseline in Mean Awake SBP and DBP by Ambulatory Blood Pressure Monitoring
Time Frame: 4 weeks
|
ANCOVA=analysis of covariance, BID=twice daily, DBP=diastolic blood pressure, FAS=full analysis set, IP=investigational product, SBP=systolic blood pressure.
|
4 weeks
|
|
Change From Baseline in Mean Sleeping SBP and DBP by Ambulatory Blood Pressure Monitoring
Time Frame: 4 weeks
|
ANCOVA=analysis of covariance, BID=twice daily, DBP=diastolic blood pressure, FAS=full analysis set, IP=investigational product, SBP=systolic blood pressure.
|
4 weeks
|
|
Mean Change From Baseline in Clinic SBP and DBP
Time Frame: 4 weeks
|
Blood pressure was measured in the clinic using an automated blood pressure machine (oscillometric method).
Three separate measurements were taken 2 to 5 minutes apart and the mean of the 2nd and 3rd measurements calculated.
ANCOVA=analysis of covariance, BID=twice daily, DBP=diastolic blood pressure, FAS=full analysis set, IP=investigational product, SBP=systolic blood pressure.
|
4 weeks
|
|
Mean Change From Baseline in Morning Pre-dose Home SBP and DBP
Time Frame: 4 weeks
|
ANCOVA=analysis of covariance, BID=twice daily, DBP=diastolic blood pressure, FAS=full analysis set, IP=investigational product, SBP=systolic blood pressure.
|
4 weeks
|
|
Mean Change From Baseline in Evening Post-dose Home SBP and DBP
Time Frame: 4 weeks
|
ANCOVA=analysis of covariance, BID=twice daily, DBP=diastolic blood pressure, FAS=full analysis set, IP=investigational product, SBP=systolic blood pressure.
|
4 weeks
|
|
Mean Change From Completion/Discontinuation to Follow-up in Clinical Measurement of SBP and DBP
Time Frame: Day 29 to Day 36
|
BID=twice daily, DBP=diastolic blood pressure, FAS=full analysis set, IP=investigational product, SBP=systolic blood pressure.
|
Day 29 to Day 36
|
|
DAS28-CRP Improvement
Time Frame: 4 weeks
|
ANCOVA=analysis of covariance, BID=twice daily, DAS28-CRP=Disease Activity Score based on a count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (C-reactive protein [CRP]) and the patient's own assessment, FAS=full analysis set, IP=investigational product.
Scores can take any positive value with a lower value indicative of a better clinical condition.
Mean changes from baseline in DAS28-CRP score are shown at each visit and are presented as decreases from baseline (defined as baseline minus post-baseline) with larger changes indicating a better clinical condition.
|
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- D4300C00033
- 2011-006070-73
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.